New drug candidate aims to calm restless legs when current meds backfire

NCT ID NCT03218969

Completed Symptom relief Sponsor: William Ondo, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small study tested whether ecopipam, a drug that blocks a specific brain receptor, can help people with restless leg syndrome whose symptoms have gotten worse from their usual dopamine-based medication. Ten adults took either ecopipam or a placebo for six weeks, then switched after a two-week break. Researchers measured changes in symptom severity and how much of the body was affected.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ecopipam (a D1 receptor antagonist, taken orally)
What this could lead to: If it works, this could offer a new way to manage RLS when standard treatments stop working or make symptoms worse.
What could go wrong: This is a very small, early-phase trial with only 10 people. Results may not apply to everyone, and the drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUGMENTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

restless legs syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUGMENTATION RESTLESS LEGS SYNDROME

Contacts and locations

Locations

Houston Methodist Hospital

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.